磷脂酰肌醇-3-激酶(PI3K)的活化及在HER-2过表达的局部晚期乳腺癌中对曲妥珠单抗及拉帕替尼的反应.pdfVIP

S-01 P13KinaseactivationandresponsetotrastuzumaborlapatinibinHER-2 overexpressinglocallyadvancedbreastcancer(LABC) *M.CarolinaGutierrez*MengfenWuHelenWong SusanG.Hilsenbeck JianHuang HugoM.HorlingsMothaffarRimawi,IleniaMigliaccio,René Bernards,**C.Kent Osborne,**CarlosArteaga,**JennyC.Chang LesterandSueSmithBreastCenter,BaylorCollegeofMedicine,Houston, TX;VanderbiltUniversity,andTheNetherlandsCancerInstitute Background:ActivatingmutationsofPI3kinase(PIK3CA)andPTENlossmaybe associatedwithtrastuzmabresistance.Trastuzumab,aHER2humanizedmonoclonal antibody,andlapatinib,anEGFR/HER2tyrosinekinaseinhibitorarebothestablished treatments. Greaterunderstandingofthecellularresponsetotrastuzumabor lapatinibisneededtotailortargetedtherapyforindividualpatientsandidentify thoselesslikelytobenefit. 磷脂酰肌醇-3-激酶(PI3K)的活化及其在HER-2过表达的局部晚期乳腺癌中对曲妥珠单抗 及拉帕替尼的反应 JennyC.Chang, 美国德克萨斯州休斯顿市贝勒医学院LesterandSueSmith乳 腺中心 背景：磷脂酰肌醇-3-激酶 （phosphatidylinosital-3-kinase，PI3K）的突变及PTEN 的缺失可能与曲妥珠单抗的耐药有关。曲妥珠单抗 （人源化HER2单克隆抗体，Herceptin） 和拉帕替尼 （EGFR/HER2酪氨酸激酶抑制剂）都是目前标准的乳腺癌靶向治疗手段。深入 了解细胞对曲妥珠单抗和拉帕替尼的反应，对于实施个体化鸡尾酒式靶向治疗是必不可少 的，也有助于鉴别出治非所宜者。 复旦大学肿瘤医院 汤立晨 S-02 New Strategy in MBC Treatment DavidMilesMountVernonHospital,UK Anti-angiogenesisplaysessentialroleinmBCtreatmentwhichhasbeenproveninphaseⅢ key clinicaltrialsofBevacizumab.CombinationBevacizumabwithchemotherapyhassuperior efficacywithgoodtolerability.Currently,Bevacizumabisusedinclinicalpracticemoreandmore widelyandrecommendedbyguidelineinmanynations.